A 3-Year, open-label, flexible-dosing study of milnacipran for the treatment of fibromyalgia

Clinical Journal of Pain

Volumn 29, Issue 12, 2013, Pages 1021-1028

  Arnold, Lesley M ^a   Palmer, Robert H ^b   Ma, Yimin ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

Author keywords

fibromyalgia; long term treatment; milnacipran; safety profile

Indexed keywords

MILNACIPRAN;

ADULT; ANXIETY; ARTHRALGIA; ARTICLE; BACKACHE; BRONCHITIS; CHOLELITHIASIS; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; CONSTIPATION; DEPRESSION; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG DOSE ESCALATION; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELEVATED BLOOD PRESSURE; FATIGUE; FEMALE; FIBROMYALGIA; HEADACHE; HEART PALPITATION; HEART RATE; HOT FLUSH; HUMAN; HYPERHIDROSIS; HYPERTENSION; INSOMNIA; LIMB PAIN; MAJOR CLINICAL STUDY; MALE; MENTAL COMPONENT SUMMARY SCORE; MUSCLE SPASM; NAUSEA; OPEN STUDY; PAIN ASSESSMENT; PATIENT GLOBAL DISEASE STATUS; PHASE 3 CLINICAL TRIAL; PHYSICAL COMPONENT SUMMARY SCORE; PRIORITY JOURNAL; RHINOPHARYNGITIS; SHORT FORM 36; SIDE EFFECT; SINUSITIS; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VISUAL ANALOG SCALE; VITAL SIGN; VOMITING; WEIGHT CHANGE;

ADOLESCENT; ADULT; AGED; ANALGESICS; CYCLOPROPANES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FIBROMYALGIA; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PAIN MEASUREMENT; PATIENT SATISFACTION; TREATMENT OUTCOME;

EID: 84887823970     PISSN: 07498047     EISSN: 15365409     Source Type: Journal    
DOI: 10.1097/AJP.0b013e31828440ab     Document Type: Article

References (30)

1. Wolfe F, Ross K, Anderson J, et al. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995;38:19-28.
2. Bennett RM. Clinical manifestations and diagnosis of fibromyalgia. Rheum Dis Clin North Am. 2009;35:215-232.
3. Arnold LM, Clauw DJ, McCarberg BH. Improving the recognition and diagnosis of fibromyalgia. Mayo Clin Proc. 2011;86:457-464.
4. Abeles AM, Pillinger MH, Solitar BM, et al. Narrative review: The pathophysiology of fibromyalgia. Ann Intern Med. 2007;146:726-734.
5. Clauw DJ, Arnold LM, McCarberg BH; FibroCollaborative. The science of fibromyalgia. Mayo Clin Proc. 2011;86:907-911.
6. Schmidt-Wilcke T, Clauw DJ. Fibromyalgia: From pathophysiology to therapy. Nat Rev Rheumatol. 2011;7:518-527.
7. Walitt B, Fitzcharles MA, Hassett AL, et al. The longitudinal outcome of fibromyalgia: A study of 1555 patients. J Rheumatol. 2011;38:2238-2246.
8. Schaefer C, Chandran A, Hufstader M, et al. The comparative burden of mild, moderate and severe fibromyalgia: Results from a cross-Sectional survey in the United States. Health Qual Life Outcomes. 2011;9:71.
9. Arnold LM, Crofford LJ, Mease PJ, et al. Patient perspectives on the impact of fibromyalgia. Patient Educ Couns. 2008;73:114-120.
10. Choy E, Perrot S, Leon T, et al. A patient survey of the impact of fibromyalgia and the journey to diagnosis. BMC Health Serv Res. 2010;10:102.
11. Mease PJ, Dundon K, Sarzi-Puttini P. Pharmacotherapy of fibromyalgia. Best Pract Res Clin Rheumatol. 2011;25: 285-297.
12. Choy E, Marshall D, Gabriel ZL, et al. A systematic review and mixed treatment comparison of the efficacy of pharmacological treatments for fibromyalgia. Semin Arthritis Rheum. 2011;41:335-345.e6.
13. Arnold LM, Emir B, Murphy TK, et al. Safety profile and tolerability of up to 1 year of pregabalin treatment in 3 openlabel extension studies in patients with fibromyalgia. Clin Ther. 2012;34:1092-1102.
14. Chappell AS, Littlejohn G, Kajdasz DK, et al. A 1-Year safety and efficacy study of duloxetine in patients with fibromyalgia. Clin J Pain. 2009;25:365-375.
15. Mease PJ, Russell IJ, Kajdasz DK, et al. Long-Term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia. Semin Arthritis Rheum. 2010;39:454-464.
16. Goldenberg DL, Clauw DJ, Palmer RH, et al. Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-Blind, monotherapy 6-Month extension study. Pain Med. 2010;11:180-194.
17. Ferrera R, Palmer R, Chen W, et al. Improvements in fibromyalgia symptoms are sustained for 1 year with milnacipran treatment: Results from 2 double-Blind, dose-Controlled extension studies [abstract]. J Pain. 2009;10(suppl):S60.
18. Branco JC, Cherin P, Montagne A, et al. Longterm therapeutic response to milnacipran treatment for fibromyalgia. A European 1-Year extension study following a 3-Month study. J Rheumatol. 2011;38:1403-1412.
19. Gendreau RM, Thorn MD, Gendreau JF, et al. Efficacy of milnacipran in patients with fibromyalgia. J Rheumatol. 2005;32:1975-1985.
20. Mease PJ, Clauw DJ, Gendreau RM, et al. The efficacy and safety of milnacipran for treatment of fibromyalgia. A randomized, double-Blind, placebo-Controlled trial. J Rheumatol. 2009;36:398-409.
21. Clauw DJ, Mease P, Palmer RH, et al. Milnacipran for the treatment of fibromyalgia in adults: A 15-Week, multicenter, randomized, double-Blind, placebo-Controlled, multiple-Dose clinical trial. Clin Ther. 2008;30:1988-2004.
22. Arnold LM, Gendreau RM, Palmer RH, et al. Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: Results of a randomized, double-Blind, placebo-Controlled trial. Arthritis Rheum. 2010;62:2745-2756.
23. A study of milnacipran in patients with fibromyalgia: Effects on 24-Hour ambulatory blood pressure monitoring. Available at: Http://clinicaltrials.gov/ ct2/show/NCT00618956. Accessed November 30, 2012.
24. Wolfe F, Smythe HA, Yunus MB, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis Rheum. 1990;33:160-172.
25. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561-571.
26. Mease PJ, Clauw DJ, Arnold LM, et al. Fibromyalgia syndrome. J Rheumatol. 2005;32:2270-2277.
27. Ware JE Jr., Sherbourne CD. The MOS 36-Item short-Form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-483.
28. Cleeland CS, Ryan KM. Pain assessment: Global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994;23:129-138.
29. Savella [prescribing information]. St. Louis, MO: Forest Laboratories, Inc.; October 2012. Available at: Http://www.savella.com. Accessed November 30, 2012.
30. Clauw D, Mease P, Ma Y, et al. A randomized, doubleblind, placebo-Controlled discontinuation study of milnacipran for the treatment of fibromyalgia in patients receiving long-Term milnacipran treatment [abstract]. J Pain. 2011; 12(suppl):P22.